Weight effects of antidiabetic agents

References

• Diabetes Fact Sheet. World Health Organization; [cited 2016 Jul]. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/
   Google Scholar
• Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes – causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799–812.
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Danne T, Hermansen K, et al. Weight-sparing effect of insulin detemir: a consequence of central nervous system-medicated reduced energy intake? Diabetes Obes Metab. 2015;17:919–927.
   PubMed Web of Science ®Google Scholar
• Jansen HJ, Vervoort GMM, de Haan AFJ, et al. Diabetes-related distress, insulin dose, and age contribute to insulin-associated weight gain in patients with type 2 diabetes: results of a prospective study. Diabetes Care. 2014;37:2710–2717.
   PubMed Web of Science ®Google Scholar
• UK Porspective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Davies MH, Derezinski T, Pedersen CB, et al. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technolo Ther. 2008;10:273–277.
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Simon AC, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;7:CD006383.
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Koenen LC, King MA, et al. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes paitents on basal-only therapy with oral antidiabetic drugs improves glycemic control and reduces weight gain and risk of hypoglycemia: 14-week follow-up data from PREDICTIVE™. Diabetes Obes Metab. 2008;10:75–81.
   PubMed Web of Science ®Google Scholar
• Ji L, Zhang P, Zhu D, et al. Comparative effectiveness and safety of different basal insulins in a real-world setting. Diabetes Obes Metab. 2017;19:1116–1126.
   PubMed Web of Science ®Google Scholar
• Boucher-Berry C, Parton EA, Alemzadeh R. Excess weight gain during insulin pump therapy is associated with higher basal insulin doses. J Diabetes Metab Disord. 2016;15:47.
   PubMed Web of Science ®Google Scholar
• Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736–1747.
   PubMed Web of Science ®Google Scholar
• Paul SK, Shaw JE, Montvida O, et al. Weight gain in insulin-treated patients by body mass index category at treatment initiation: new evidence from real-word data in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:1244–1252.
   PubMed Web of Science ®Google Scholar
• Bramlage P, Bluhmki T, Fleischmann H, et al. Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry. BMJ Open Diabetes Res Care. 2017;4:e000301.
   Google Scholar
• Bisenbach G, Raml A, Alsaraji N. Weight gain and insulin requirement in type 2 diabetic patients during the first year after initiating insulin therapy dependent on baseline BMI. Diabetes Obes Metab. 2006;8:669–673.
   PubMed Web of Science ®Google Scholar
• Aas A, Ohrvik J, Malmberg K, et al. Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 study. Diabetes Obes Metab. 2009;11:323–329.
   PubMed Web of Science ®Google Scholar
• Mitri J, Hamdy O. Diabetes medications and body weight. Expert Opin Drug Saf. 2009;8:573–584.
   PubMed Web of Science ®Google Scholar
• Sheehan AH. Weight Gain. In: Tisdale JE, Miller DA, editors. Drug-induced diseases. Prevention detection and management. Bethesda (MD): American Society of Health-System Pharmacists; 2006. p. 409–519.
   Google Scholar
• Malone M. Medications associated with weight gain. Ann Pharmacother. 2005;39:2046–2055.
   PubMed Web of Science ®Google Scholar
• Derosa G, Limas CP, Macías PC, et al. Dietary and nutraceutical approach to type 2 diabetes. Arch Med Sci. 2014;10:336–344.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care. 2017;40:S1–S138. DOI:10.2337/dc17-S011.
   PubMed Web of Science ®Google Scholar
• Phung OJ, Scholle JM, Talwar M, et al. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in Type 2 diabetes. Jama. 2010;303:1410–1418.
   PubMed Web of Science ®Google Scholar
• Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2015;109:378–388.
   PubMed Web of Science ®Google Scholar
• Kim SS, Kim IJ, Lee KJ, et al. Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: a multicenter randomized double-blind study. J Diabetes. 2017;9:412–422.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Lauring B, Gantz I, et al. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017 Jun 28;33:1–8. [Epub ahead of print].
   Web of Science ®Google Scholar
• Del prato S, Fleck P, Wilson C, et al. Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18:623–627.
   PubMed Web of Science ®Google Scholar
• Domecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:363–370.
   PubMed Web of Science ®Google Scholar
• Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11:840–848.
   PubMed Web of Science ®Google Scholar
• Starlix (nateglinide) [product information]. East Hanover (NJ): Novartis; 2013.
   Google Scholar
• Prandin (repaglinide) [product information]. Princeton (NJ): Novo Nordisk Inc; 2014.
   Google Scholar
• Moses RG, Gomis R, Frandsen KB, et al. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes Care. 2001;24:11–15.
   PubMed Web of Science ®Google Scholar
• Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013;12:153–175.
   PubMed Web of Science ®Google Scholar
• Alemán-González-Duhart D, Tamay-Cach F, Álvarez-Almazán S, et al. Current advances in the biochemical and physiological aspects of the treatment of type 2 diabetes mellitus with thiazolidinediones. PPAR Res. 2016;2016:7614270.
   PubMed Web of Science ®Google Scholar
• Actos (pioglitazone) [product information]. Deerfield (IL): Takeda Pharmaceuticals America Inc; 2008.
   Google Scholar
• Avandia (rosiglitazone) [product information]. Research Triangle Park (NC): GlaxoSmithKline; 2009.
   Google Scholar
• Adachi H, Katsuyama H, Yanai H. The low dose (7.5mg/day) pioglitazone is beneficial to the improvement in metabolic parameters without weight gain and an increase of risk for heart failure. Int J Cardiol. 2017;227:247–248.
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Dutta P, Hota D, et al. Effect of low dose pioglitazone on glycemic control and insulin resistance in type 2 diabetes: a randomized, double blind, clinical trial. Diabetes Res Clin Pract. 2015;109:e32–5.
   PubMed Web of Science ®Google Scholar
• Majima T, Komatsu Y, Doi K, et al. Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. Endocr J. 2006;53:325–330.
   PubMed Web of Science ®Google Scholar
• Panikar V, Kale NJ, Hoskote SS, et al. Effect of Low (7.5 mg/day), Standard (15 mg/day) and High (30 mg/day) dose pioglitazone therapy on glycemic control and weight gain in recently-diagnosed type 2 diabetes patients. J Assoc Phys India. 2015;63:36–39.
   PubMedGoogle Scholar
• Derosa G, Cicero AF, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther. 2004;26:744–754.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Bailey CJ. Oral antidiabetic agents current role in type 2 diabetes. Mellitus Drugs. 2005;65:385–411.
   Google Scholar
• Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:398–403.
   Web of Science ®Google Scholar
• Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374:1677–1686.
   PubMed Web of Science ®Google Scholar
• Thrasher J. Pharmacologic management of type 2 diabetes mellitus: available therapies. Am J Med. 2017;130:S4–S17.
   PubMed Web of Science ®Google Scholar
• Hussain M, Atif MA, Tunio AG, et al. Effect of sitagliptin on glycemic control, body weight, blood pressure and serum lipid profile in type 2 diabetic hyperlipidemic patients. J Ayub Med Coll Abbottabad. 2016;28:369–372.
   Google Scholar
• Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag. 2010;6:541–548.
   PubMedGoogle Scholar
• Potts JE, Gray LJ, Brady EM, et al. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One. 2015;10:e0126769. DOI:10.1371/journal.pone.0126769.
   PubMed Web of Science ®Google Scholar
• Crane J, McGowan B. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity. Ther Adv Chronic Dis. 2016;7:92–107.
   PubMed Web of Science ®Google Scholar
• Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies. Diabetes Obes Metab. 2009;11:26–34.
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, et al. LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 Mono): a randomised, 52-week, phase III, double blind, parallel-treatment trial. Lancet. 2009;373:473–481.
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, et al. LEAD-4 study investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224–1230.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes. The SCALE diabetes randomized clinical trial. JAMA. 2015;314:687–699.
   PubMed Web of Science ®Google Scholar
• Marso S, Bain S, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14:5–14.
   PubMed Web of Science ®Google Scholar
• Neeland IJ, McGuire DK, Chilton R, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13:119–126.
   PubMed Web of Science ®Google Scholar
• Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016;6:e009417. DOI:10.1136/bmjopen-2015-009417.
   PubMed Web of Science ®Google Scholar
• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–274.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17:936–948. DOI:10.1111/dom.12503.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37:1815–1823. DOI:10.2337/dc13-3055.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38:403–411.
   PubMed Web of Science ®Google Scholar
• Wilding J, Woo V, Solder N, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med. 2012;156:405–415.
   PubMed Web of Science ®Google Scholar
• Wilding J, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diab Obes Metab. 2014;16:124–136.
   PubMed Web of Science ®Google Scholar
• Your Weight and Diabetes. The Obesity Society; [cited 2015 Feb]. Available from: http://www.obesity.org/content/weight-diabetes
   Google Scholar
• National Diabetes Statistics Report. National center for chronic disease prevention and health promotion; 2017. [cited 2017 Oct 10]. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf1
   Google Scholar
• International Diabetes Federation. Recommendations For Managing Type 2 Diabetes In Primary Care; 2017. [cited 2017 Oct 10]. Available from: www.idf.org/managing-type2-diabetes
   Google Scholar